Cypress Bails After All
Schizophrenia Drug Returns to BioLineRx; Phase IIb Next
By Jennifer Boggs
Friday, May 13, 2011
The licensing deal that spurred a hostile takeover attempt by disgruntled shareholders at Cypress Bioscience Inc. and eventually led to this year's buyout of the San Diego-based firm by Ramius LLC and Royalty Partners has come to an end.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.